Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.100
-0.020 (-1.79%)
Aug 1, 2025, 4:00 PM - Market closed
Pyxis Oncology Revenue
In the year 2024, Pyxis Oncology had annual revenue of $16.15M.
Revenue (ttm)
$16.15M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
68.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.15M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
PYXS News
- 4 weeks ago - Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Pyxis Oncology to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC - GlobeNewsWire
- 4 months ago - Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - GlobeNewsWire
- 4 months ago - Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - GlobeNewsWire
- 4 months ago - Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - GlobeNewsWire